Navigation Links
BioMed Realty Trust Announces Retirement of Mark Riedy From Its Board of Directors
Date:4/15/2008

SAN DIEGO, April 15 /PRNewswire-FirstCall/ -- BioMed Realty Trust, Inc. (NYSE: BMR) today announced that Mark Riedy will retire from its board of directors concurrently with the company's annual meeting of stockholders, scheduled for May 21, 2008.

Dr. Riedy, the Ernest W. Hahn Professor of Real Estate Finance and Executive Director of the Burnham-Moores Center for Real Estate at the University of San Diego, has been a member of the company's board of directors since its initial public offering in 2004, and also served as a member of the board's compensation committee and as past chair and current member of the board's audit committee.

"We are thankful for all of Mark's valuable contributions to BioMed over the past four years," said Alan Gold, President and Chief Executive Officer of BioMed Realty Trust. "During his tenure, BioMed has grown from 13 properties, representing an aggregate of 2.3 million rentable square feet, at its initial public offering in 2004 to 68 properties, representing 8.5 million rentable square feet and 1.9 million square feet of development in progress, which are positioned in some of the country's most sought-after locations for life science space. His insight and experience have helped advance BioMed to where it is today, with the solid financial and operational foundation upon which we will continue to execute on our mission of being the leading provider of real estate to the life science industry."

About BioMed Realty Trust

BioMed Realty Trust, Inc. is a real estate investment trust (REIT) focused on Providing Real Estate to the Life Science Industry(R). The company's tenants primarily include biotechnology and pharmaceutical companies, scientific research institutions, government ag
'/>"/>

SOURCE BioMed Realty Trust, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Boston Biomedical Research Institute Maintains Baa3 Rating from Moodys
2. SBT Acquisition Inc. Successfully Completes Tender Offer for Shares of Lifecore Biomedical, Inc.
3. BioMed Realty Trust Announces Increase in Quarterly Common Stock Dividend
4. Sigma-Aldrich, Oxford BioMedica and Open Biosystems Settle Patent Dispute Over Use of LentiVector Technology in Research Reagents
5. Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO) With $3.52 Price Target
6. LifeNet Health(R) Unveils New Biomedical Spine Implant
7. MIT researcher addresses biomedical engineering challenges
8. mNEMOSCIENCE GmbH Announces Global Licensing Agreement With Aporo Biomedical
9. BioMed Realty Trust Announces Tax Treatment of 2007 Distributions
10. BioMed Realty Trust To Report 2007 Fourth Quarter and Year-End Results
11. Bookham to Enter Biomedical Illumination Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... Dec. 2 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ... dose confirmation and dosimetry trial of Cotara® in patients ... brain cancer. Cotara is a targeted monoclonal antibody ... new treatment for GBM. Cotara specifically targets cells ...
(Date:12/2/2009)... - "Bolstering Biodiversity in Africa: ... Coinciding with the International Year of Biodiversity, ... international conference in Libreville,(Gabon) on the issue of ... attended by government and state leaders, ministers,scientific experts, ...
(Date:12/2/2009)... TechConnect World, an event bringing together the ... cleantech, nanotech, biotech and MEMS, announced the December ... ,, Now in its 14th year, TechConnect World, ... Institute (NSTI), and the Clean Technology and Sustainable ...
(Date:12/2/2009)... Ltd today announced data presentations on its novel oral ... 51st Annual Meeting and Exposition in New Orleans. ,, ... the Phase 1 dose-escalation trial of SB1518 detailing its ... ranging from 100 to 600 mg. These doses were ...
Breaking Biology Technology:Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5Libreville International Conference 2-3 June 2010 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5
... clinical-stage biopharmaceutical company focused on diseases of epidemic potential, ... for SQ109 with the dosing of the first cohort ... replace one or more of the current first-line antitubercular ... Fast Track designation and FDA/EMEA Orphan Drug Designation in ...
... Syrinx Consulting Corporation , an IT consulting ... SharePoint applications , announced today that ... a leading biopharmaceutical company in the Boston area. ... gigabytes of data from a SharePoint 2003 environment to ...
... biotechnology research is providing new applications for nutraceutical ... two leading health concerns among consumers. Leading ... www.advanascience.com , will present future ... consumer healthy category at VitaFoods International on Wednesday, ...
Other Biology Technology:Sequella Commences Phase 1B Study for New Tuberculosis Drug SQ109 2Syrinx Wins Contract with Leading Pharmaceutical Company for SharePoint 2007 Services 2Industry Expert Reveals Cutting Edge Biotechnology Science for Nutraceutical and Functional Food Applications 2
(Date:12/4/2009)... amyloids the fibrous protein deposits associated with diseases such ... potential new area for therapeutics. , It was believed that ... known as fibres - are inert, but that there may ... and cause disease. , But in a paper published ...
(Date:12/3/2009)... co-workers discovered that specific types of human papillomavirus (HPV) ... pathogens cause cells to degenerate. It is known today ... E7. Both proteins switch off different cellular control functions, ... Rsl and his co-workers at DKFZ have now discovered ...
(Date:12/3/2009)... likened to emptying a museum of its collection, or dumping ... replacing every local cuisine with McDonald,s burgers. , But the ... the world boring. New research now suggests it may also ... , "Habitat destruction and biodiversity loss,"driven by the replacement of ...
Breaking Biology News(10 mins):New therapy targets for amyloid disease 2Papillomavirus silences innate immune response 2Species down, disease up 2Species down, disease up 3Species down, disease up 4Lives Compromised and Patient Access Limited with New Cuts to Medicare 62021 1Lives Compromised and Patient Access Limited with New Cuts to Medicare 62021 2Statement of Support 3A Strengthening Oral Health Care is Key Part of Health Reform 62018 1Statement of Support 3A Strengthening Oral Health Care is Key Part of Health Reform 62018 2Shire Submits European Marketing Authorization Application 28MAA 29 for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 14957 1Shire Submits European Marketing Authorization Application 28MAA 29 for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 14957 2Shire Submits European Marketing Authorization Application 28MAA 29 for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 14957 3
... WASHINGTON Members of the public can send their ... mission dedicated to understanding the effects of particles in ... , The "Send Your Name Around the Earth" Web ... mission and place their names in orbit for years ...
... Enhanced Applicant,Verification and New Security Features that Combat ... 25 L-1 Identity,Solutions, Inc. (NYSE: ID ... today announced that the Massachusetts Registry of Motor ... a new six-year,contract to upgrade and further enhance ...
... surrounded by the San Bernardino National Forest have taken ... to a U.S. Forest Service study completed this summer., ... A Case Study on the San Bernardino National Forest," ... surveys and focus group discussions in 2007 had taken ...
Other Biology News:Send your name around the Earth on NASA'S Glory mission 2L-1 Identity Solutions Awarded New Massachusetts RMV Driver's License Contract Valued at an Estimated $32 Million 2L-1 Identity Solutions Awarded New Massachusetts RMV Driver's License Contract Valued at an Estimated $32 Million 3Study reveals homeowner perceptions in fire-prone areas 2
...
... Cell Lines stably express the regulatory ... line is functionally tested for induction ... expression control vector pGene/V5-His/lacZ and by ... with mifepristone (Figure 1). These cell ...
... Kit Includes: Sufficient library for ... x 10^9 independent sequences, -28 gIII ... DNA sequencing, -96 gIII Sequencing Primer ... Host E. coli strain ER2738, Control ...
... Materials for 15-20 enhancements when ... Western Blot Signal Enhancement System is designed to ... is an excellent tool for evaluating proteins with low ... to pre-treat membrane prior to blocking the membrane; 1x ...
Biology Products: